A biotechnology company developing phage therapies for treating bacterial infections.
On December 1, 2014 Pherecydes Pharma completed their series A funding round with €1.9 million in funding from Auriga Partners.
On January 16, 2018 Pherecydes Pharma completed their series A funding round with €8.7 million in funding from Go Capital (lead investor), Omnes Capital, FaDiese, Auriga Partners, and ACE Management.